Key result
Paroxetine shows no benefit over matched controls for 28-day mortality in heart failure.
Why the study?
Evidence regarding the impact of paroxetine on heart failure remains scarce, prompting an assessment of its association with mortality.
Does paroxetine reduce 28-day all-cause mortality in hospitalized patients with heart failure?
Cohort (n=11,657)
No
Does paroxetine reduce 28-day all-cause mortality in hospitalized patients with heart failure?
In a retrospective cohort of hospitalized heart failure patients, paroxetine use was not associated with a significant reduction in 28-day all-cause mortality.
No mortality benefit seen with paroxetine in this HF cohort; leaves open any role pending prospective trials.
INTRODUCTION: ; however, evidence of its impact on heart failure remains scarce. METHODS: To assess the association between paroxetine use and mortality in patients with heart failure. We conducted a retrospective longitudinal cohort study from 2008 to 2019, with a follow-up time of 28 days for all groups. This is a single-center study using the Medical Information Mart for Intensive Care IV database with 11,657 heart failure patients identified. We performed genetic matching to adjust for the covariates. Heart failure patients prescribed paroxetine for >24 h after hospital admission were categorized into the paroxetine group (77 patients), with remaining heart failure patients making up the matched control group (231 patients). The primary outcome was 28-day all-cause mortality from the date of hospital admission. Secondary outcomes included length of intensive care unit stay, length of hospital stay, and in-hospital mortality. The Kaplan-Meier survival estimator, logistic regression, Cox regression, and restricted mean survival time were used to detect the association between paroxetine therapy and outcomes. CONCLUSIONS: In patients with heart failure, treatment with paroxetine did not significantly reduce 28-day all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) conducted a cohort in Heart failure (n=11,657). Paroxetine vs. No paroxetine was evaluated on 28-day all-cause mortality (HR 1.00, 95% CI 0.42-2.62, p=0.92). In patients with heart failure, treatment with paroxetine did not significantly reduce 28-day all-cause mortality compared to matched controls (HR 1.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: